This second round of funding raises the equivalent of $45.4 million to support the advancement of Oxford-based Evox’s exosome-based therapeutics pipeline, including pushing several rare disease ...

07, 2022 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, today announced that the Company has been granted four new patents covering a ...

Prior to Evox, he founded and led IsletOne Therapeutics, a cell therapy company developing ... developed a dominant IP estate and advanced the Company’s proprietary pipeline towards the clinic. “On ...

Evox Therapeutics Presents Progress Across its DeliverEX® Platform Highlighting Advances in Exosome-Mediated Delivery of Genetic Medicines Including Gene Editing and RNA Therapeutics OXFORD, United ...

OXFORD, United Kingdom, May 17, 2023 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, today announced that the Company has been granted ...

Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, has purchased Codiak Biosciences engEx-AAV™ technology platform, including all intellectual ...

OXFORD, United Kingdom, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd ('Evox'), a leading exosome therapeutics company, today announced a research collaboration and option agreement with ...

About Evox Therapeutics Evox Therapeutics is a privately held, Oxford-based biotechnology company that is a leader in harnessing and engineering the natural delivery capabilities of extracellular ...

OXFORD, United Kingdom, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, today announced that the Company has been granted ...